TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30694523

Group type: EXPERIMENTAL
Intervention: Bevacizumab with neoadjuvant chemotherapy (NCT)
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NCT)
Number of subjects: 1160
Study: 30477773

Group type: EXPERIMENTAL
Intervention: Miniscrews
Number of subjects: 80

Group type: COMPARATOR
Intervention: Molar blocks
Number of subjects: 80
Study: 26497831

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation providing 1400 mg per day EPA+DHA
Number of subjects: 261

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 261
Study: 24003005

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - summary of family psychosocial risk information provided to the medical team
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control Group (CG) - no summary of family psychosocial risk information provided
Number of subjects: 67
Study: 23134960

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation of auricular Shenmen point (group A)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation of auricular Eye point (group B)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 180
Study: 20872127

Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 111
Study: 17465862

Group type: EXPERIMENTAL
Intervention: LT4/LT3 combined therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: LT4 monotherapy
Number of subjects: 20
Study: 15284043

Group type: EXPERIMENTAL
Intervention: Surgical abortions performed by physician assistants
Number of subjects: 1363

Group type: COMPARATOR
Intervention: Surgical abortions performed by physicians
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: History of pelvic inflammatory disease
Number of subjects: 1363
Study: 11487166

Group type: EXPERIMENTAL
Intervention: 3 g of amoxicillin
Number of subjects: 70

Group type: COMPARATOR
Intervention: 3 g of placebo control
Number of subjects: 70
Study: 9921941

Group type: EXPERIMENTAL
Intervention: Postoperative radiochemotherapy
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Adjuvant radiotherapy
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Conventional radiochemotherapy
Number of subjects: 1104

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 1104
Study: 7917898

Group type: EXPERIMENTAL
Intervention: Death-education course
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (freshman students not taking the course)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Combined groups (course attendees and controls)
Number of subjects: 168
Study: 3294124

Group type: EXPERIMENTAL
Intervention: Combined therapy with cimetidine 1 g daily and cisapride 40 mg daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Single drug therapy (cimetidine and placebo)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combined therapy with cimetidine + cisapride
Number of subjects: 47
Study: 31567794

Group type: EXPERIMENTAL
Intervention: Acemannan sponge graft
Number of subjects: 30

Group type: COMPARATOR
Intervention: Blood clot control
Number of subjects: 30
Study: 28651586

Group type: EXPERIMENTAL
Intervention: OncoActive intervention (computer-tailored physical activity program)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Usual care waiting-list control group
Number of subjects: 428
Study: 26025245

Group type: EXPERIMENTAL
Intervention: ICG-(99m)Tc-nanocolloid
Number of subjects: 40

Group type: COMPARATOR
Intervention: (99m)Tc-nanocolloid
Number of subjects: 40
Study: 24355343

Group type: EXPERIMENTAL
Intervention: Active telephone-based recruitment strategy (email invitation and 1 to 3 follow-up phone calls)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Passive recruitment strategy (informed via newsletters)
Number of subjects: 128
Study: 21765368

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg once daily for 7 days with fimasartan 240 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg once daily for 7 days
Number of subjects: 24
Study: 19835119

Group type: EXPERIMENTAL
Intervention: Warming needling treatment combined with cupping (needle inserted on sciatic nerve at Huantiao (GB 30))
Number of subjects: 150

Group type: COMPARATOR
Intervention: Warming needling treatment combined with cupping (needle not needled on sciatic nerve)
Number of subjects: 150
Study: 17342038

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 0
Study: 15008676

Group type: EXPERIMENTAL
Intervention: Participants trained with features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transformation tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Removal of features at correct and geometrically equivalent corners
Number of subjects: 0
Study: 11563999

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: Ibuprofen 2400 mg daily
Number of subjects: 1516

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: H. pylori infection
Number of subjects: 1516
Study: 9700954

Group type: COMPARATOR
Intervention: Hyperglycemia (15 mM)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bombesin infusion (1 ng/kg x min) during hyperglycemia
Number of subjects: 7
Study: 7716349

Group type: EXPERIMENTAL
Intervention: Bamiphylline (600 mg b.d. for 15 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (600 mg b.d. for 15 days)
Number of subjects: 20
Study: 2528737

Group type: EXPERIMENTAL
Intervention: Zoladex + flutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoladex
Number of subjects: 0
Study: 861125

Group type: EXPERIMENTAL
Intervention: Glutethimide
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31079080

Group type: EXPERIMENTAL
Intervention: £20 activity enabling vouchers every month for a year
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Support worker
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Trained peer mentor
Number of subjects: 64
Study: 29096157

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25462653

Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 480
Study: 24512796

Group type: EXPERIMENTAL
Intervention: Patients with MS
Number of subjects: 53
Study: 22496775

Group type: EXPERIMENTAL
Intervention: Ad5 seropositive participants who later acquired HIV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad35 seropositivity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ad5 seropositive participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad5 seronegative subjects
Number of subjects: 0
Study: 19841526

Group type: EXPERIMENTAL
Intervention: Theophylline (5mg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17563596

Group type: EXPERIMENTAL
Intervention: Nursing education program
Number of subjects: 841
Study: 15453517

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11339586

Group type: EXPERIMENTAL
Intervention: Mersilene mesh
Number of subjects: 56

Group type: COMPARATOR
Intervention: Autogenous fascia lata
Number of subjects: 56
Study: 9701388

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (i.v.Ig) prophylaxis
Number of subjects: 633

Group type: COMPARATOR
Intervention: Control (no i.v.Ig)
Number of subjects: 633
Study: 8017316

Group type: EXPERIMENTAL
Intervention: Diltiazem CD (DCD) 60 mg
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Diltiazem CD (DCD) 120 mg
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Diltiazem CD (DCD) 240 mg
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Diltiazem CD (DCD) 360 mg
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Diltiazem CD (DCD) 480 mg
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Diltiazem CD (DCD)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 2400071

Group type: EXPERIMENTAL
Intervention: Brain laryngeal mask airway
Number of subjects: 100

Group type: COMPARATOR
Intervention: Guedel oral airway
Number of subjects: 100
Study: 71602

Group type: EXPERIMENTAL
Intervention: (−)‐deprenyl 10 mg daily or on alternate days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: (−)‐deprenyl
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: (−)‐deprenyl with levodopa and carbidopa
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: (−)‐deprenyl with smaller total daily doses of levodopa and a peripheral decarboxylase inhibitor
Number of subjects: 41
Study: 30942013

Group type: EXPERIMENTAL
Intervention: Intradermal needling after pterygium resection
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (only pterygium resection)
Number of subjects: 76
Study: 29423177

Group type: COMPARATOR
Intervention: Neonatal vitamin A supplementation (placebo-controlled)
Number of subjects: 10644
Study: 26315154

Group type: EXPERIMENTAL
Intervention: VIP ON (Ventricular Intrinsic Preference algorithm)
Number of subjects: 389

Group type: COMPARATOR
Intervention: VIP OFF (Control group)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: VIP ON
Number of subjects: 389

Group type: COMPARATOR
Intervention: VIP OFF
Number of subjects: 389
Study: 23137103

Group type: EXPERIMENTAL
Intervention: Propofol (1%) administered at a dose of 3 mg·kg(‐1) intravenously, maintained by propofol infusion (0.5%) at 12 mg·kg(‐1·) h(‐1) for the first 20 min and at 8 mg·kg(‐1·) h(‐1) thereafter
Number of subjects: 0
Study: 21450602

Group type: EXPERIMENTAL
Intervention: High-intensity interval training for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 40
Study: 19336356

Group type: EXPERIMENTAL
Intervention: Environmental and educational intervention promoting water consumption (water fountains installed, 4 classroom lessons)
Number of subjects: 2950

Group type: EXPERIMENTAL
Intervention: Environmental and educational intervention promoting water consumption
Number of subjects: 2950

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2950
Study: 16564939

Group type: EXPERIMENTAL
Intervention: Morning hemodialysis
Number of subjects: 1845

Group type: COMPARATOR
Intervention: Midday hemodialysis
Number of subjects: 1845
Study: 16373890

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (75-min session consisting of four 15-min periods of walking on a treadmill to a target heart rate of 140 bpm and three 5-min rest periods)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Treatment of hypoglycemia with 15 g of oral glucose
Number of subjects: 50
Study: 12727976

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.043 mg/kg x d
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10483950

Group type: EXPERIMENTAL
Intervention: Suboptimal stenting
Number of subjects: 265

Group type: COMPARATOR
Intervention: Optimal stenting
Number of subjects: 265
Study: 8607484

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms q.i.d.
Number of subjects: 374

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 374
Study: 1752708

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7064012

Group type: EXPERIMENTAL
Intervention: Tizolemide 100 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30365255

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with multi‐mode analgesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Simple multi‐mode analgesia (Control)
Number of subjects: 40
Study: 27823868

Group type: COMPARATOR
Intervention: Saxagliptin
Number of subjects: 720

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 720
Study: 25742759

Group type: EXPERIMENTAL
Intervention: 150 mg losartan
Number of subjects: 3843

Group type: COMPARATOR
Intervention: 50 mg losartan
Number of subjects: 3843

Group type: EXPERIMENTAL
Intervention: Increase in SCr >0.3 mg/dl
Number of subjects: 3843

Group type: EXPERIMENTAL
Intervention: Increase in SCr >0.3 mg/dl before 4 months
Number of subjects: 3843
Study: 23763558

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 4% articaine with 1:200,000 epinephrine
Number of subjects: 30
Study: 20622687

Group type: EXPERIMENTAL
Intervention: Clevidipine (0.5 mg/mL in 20% lipid solution, initiated at 10 mg/h and titrated to effect)
Number of subjects: 22
Study: 16944000

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) simulation training, practiced two times over 3 weeks, 40 minutes each session.
Number of subjects: 77

Group type: COMPARATOR
Intervention: Traditional class attendance (control group).
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) simulation training.
Number of subjects: 77
Study: 16874784

Group type: EXPERIMENTAL
Intervention: Knee pain
Number of subjects: 6641

Group type: EXPERIMENTAL
Intervention: Clinician diagnosis of knee OA
Number of subjects: 6641
Study: 12634464

Group type: EXPERIMENTAL
Intervention: (153)Sm‐EDTMP
Number of subjects: 18

Group type: COMPARATOR
Intervention: pamidronate disodium
Number of subjects: 18
Study: 10696837

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitor therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ablation techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic follow-up
Number of subjects: 0
Study: 9125824

Group type: EXPERIMENTAL
Intervention: Wavelet and wavelet packet compression (8:1 compression)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wavelet and wavelet packet compression (16:1 compression)
Number of subjects: 0
Study: 8252157

Group type: COMPARATOR
Intervention: Ceftazidime alone 3 g/day (Group C)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ceftazidime 3 g/day plus amikacin 15 mg/kg/day (Group CA)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ceftazidime 3 g/day plus vancomycin 1.5 g/day (Group CV)
Number of subjects: 102
Study: 3896716

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 29741974

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum pressure of 8 mm Hg (n=18)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum pressure of 12 mm Hg (n=18)
Number of subjects: 36
Study: 27288307

Group type: EXPERIMENTAL
Intervention: Tβ4-pre-treated EPC transplantation (experimental group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: EPC transplantation (control group)
Number of subjects: 10
Study: 25491069

Group type: EXPERIMENTAL
Intervention: Stepped psychosocial care (screening for distress, doctor consultation, transferal to consultation liaison service)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 1000
Study: 22781566

Group type: EXPERIMENTAL
Intervention: Shadow boxing exercise for 3 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional out‐hospital management
Number of subjects: 70
Study: 20424219

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 69

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 69
Study: 18695132

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 695

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy with extracapsular tumor growth
Number of subjects: 695
Study: 15939243

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) therapy for 2 months
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) therapy
Number of subjects: 47
Study: 12818902

Group type: EXPERIMENTAL
Intervention: Long chain polyunsaturated fatty acids (LCPUFA), including docosahexaenoic acid (DHA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10365035

Group type: EXPERIMENTAL
Intervention: Heidelberg retina tomograph (HRT) analysis in converters
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 26
Study: 8916749

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (8.4 g a day)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Sucrose chewing gum (control)
Number of subjects: 306
Study: 1927519

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) dose regimen of 15 IU/m2/week as daily s.c. injections
Number of subjects: 32

Group type: COMPARATOR
Intervention: Growth hormone (GH) dose regimen of 30 IU/m2/week
Number of subjects: 32
Study: 6350994

Group type: EXPERIMENTAL
Intervention: Intravenous guanethidine block
Number of subjects: 19

Group type: COMPARATOR
Intervention: Stellate ganglion block
Number of subjects: 19
Study: 30732624

Group type: EXPERIMENTAL
Intervention: Carer-administration of as-needed subcutaneous medication for breakthrough symptoms (pain, nausea, restlessness, noisy breathing) with manualised training package delivered by local nursing team.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control arm).
Number of subjects: 0
Study: 29742243

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg/day)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: NTI‐tss
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Non‐occlusal splint
Number of subjects: 97
Study: 27346173

Group type: EXPERIMENTAL
Intervention: Lottery-based commitment device
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 163
Study: 24650849

Group type: EXPERIMENTAL
Intervention: Low radiation CTLS with 150 mAs tube current and 120 kVp tube voltage (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low radiation CTLS with 230 mAs tube current and 100 kVp tube voltage (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (filtered back-projection)
Number of subjects: 0
Study: 22962971

Group type: EXPERIMENTAL
Intervention: Brief dynamic psychotherapy (12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Brief dynamic psychotherapy
Number of subjects: 40
Study: 20884622

Group type: EXPERIMENTAL
Intervention: Autologous tumor lysate- and KLH-pulsed DC vaccine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: DCs activated with CD40L
Number of subjects: 26

Group type: COMPARATOR
Intervention: KLH-specific immune responses
Number of subjects: 26
Study: 18629727

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 128
Study: 15982130

Group type: EXPERIMENTAL
Intervention: Feature search task with preknowledge of target dimension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsearch task with preknowledge of target dimension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial-by-trial cueing with preknowledge of target dimension
Number of subjects: 0
Study: 12373264

Group type: EXPERIMENTAL
Intervention: Comprehensive social worker-based education program and environmental control
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1033
Study: 10648338

Group type: EXPERIMENTAL
Intervention: Propofol/sufentanil anesthesia (0.01 microg. kg(‐1). min(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enflurane anesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol/sufentanil anesthesia
Number of subjects: 20
Study: 8710194

Group type: EXPERIMENTAL
Intervention: Medium-latency responses (MLR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-latency responses (SLR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conduction velocity of afferent fibres mediating FDB MLR
Number of subjects: 0
Study: 1506154

Group type: EXPERIMENTAL
Intervention: Gadoteridol
Number of subjects: 122
Study: 6522737

Group type: EXPERIMENTAL
Intervention: Counseling sessions (6 sessions over 6 months)
Number of subjects: 163

Group type: COMPARATOR
Intervention: No counseling (Control group)
Number of subjects: 163
Study: 31016897

Group type: EXPERIMENTAL
Intervention: Multimodal intervention (individualized resistance exercise for 16 weeks, structured diabetes and nutritional education over seven sessions, investigator-linked training)
Number of subjects: 964

Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of the intervention
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Secondary outcomes (mortality, hospitalization, institutionalization, quality of life, burden on caregivers, frequency and severity of hypoglycaemia episodes)
Number of subjects: 964
Study: 29289798

Group type: EXPERIMENTAL
Intervention: Moral stories emphasizing actors' negative emotions toward their nonhelping behavior
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Other moral stories with a helping theme
Number of subjects: 322

Group type: COMPARATOR
Intervention: Nonmoral story (control group)
Number of subjects: 322
Study: 26510632

Group type: EXPERIMENTAL
Intervention: Dog visits
Number of subjects: 100

Group type: COMPARATOR
Intervention: Robot seal visits
Number of subjects: 100

Group type: COMPARATOR
Intervention: Soft toy cat visits
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Experimental period (all visit types)
Number of subjects: 100
Study: 25098116

Group type: EXPERIMENTAL
Intervention: Metipred and cyclosporine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional prevention (topical corticosteroids)
Number of subjects: 27